3,577 Shares in DexCom, Inc. (NASDAQ:DXCM) Acquired by Tradewinds LLC.

Tradewinds LLC. purchased a new stake in DexCom, Inc. (NASDAQ:DXCM) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 3,577 shares of the medical device company’s stock, valued at approximately $278,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in DXCM. Geode Capital Management LLC boosted its stake in DexCom by 2.2% in the third quarter. Geode Capital Management LLC now owns 9,937,604 shares of the medical device company’s stock valued at $664,056,000 after acquiring an additional 214,136 shares in the last quarter. Jennison Associates LLC increased its position in DexCom by 10.3% during the fourth quarter. Jennison Associates LLC now owns 7,643,757 shares of the medical device company’s stock worth $594,455,000 after buying an additional 710,858 shares during the period. Norges Bank acquired a new position in shares of DexCom in the 4th quarter valued at $385,367,000. Groupama Asset Managment raised its position in DexCom by 1.1% in the 3rd quarter. Groupama Asset Managment now owns 2,851,556 shares of the medical device company’s stock valued at $1,912,000 after purchasing an additional 31,358 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in DexCom by 3.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,825,206 shares of the medical device company’s stock worth $219,716,000 after purchasing an additional 91,051 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Trading Down 1.4 %

Shares of DXCM stock opened at $67.32 on Wednesday. The stock has a market cap of $26.31 billion, a P/E ratio of 47.08, a P/E/G ratio of 2.30 and a beta of 1.28. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $141.99. The business has a fifty day simple moving average of $81.62 and a 200-day simple moving average of $77.11.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. On average, analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on DXCM shares. Morgan Stanley increased their target price on shares of DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research note on Friday, February 14th. Baird R W raised DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Citigroup boosted their target price on DexCom from $101.00 to $104.00 and gave the company a “buy” rating in a report on Tuesday, March 4th. Wells Fargo & Company reaffirmed an “overweight” rating on shares of DexCom in a report on Saturday, March 8th. Finally, Redburn Atlantic raised shares of DexCom from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $85.00 to $115.00 in a research note on Monday, February 3rd. Five investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $99.82.

Insider Buying and Selling

In related news, COO Jacob Steven Leach sold 2,634 shares of DexCom stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $228,920.94. Following the completion of the sale, the chief operating officer now owns 268,644 shares in the company, valued at approximately $23,347,850.04. This trade represents a 0.97 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Kevin R. Sayer sold 33,359 shares of the company’s stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the completion of the transaction, the chief executive officer now owns 319,037 shares in the company, valued at approximately $27,727,505.67. This trade represents a 9.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 105,009 shares of company stock worth $8,044,178 in the last ninety days. Insiders own 0.30% of the company’s stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.